Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Spero Therapeutics (SPRO) over the last 8 years, with Q3 2025 value amounting to $2.4 million.

  • Spero Therapeutics' Current Deferred Revenue fell 9048.85% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 9048.85%. This contributed to the annual value of $21.8 million for FY2024, which is 1290.98% down from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' Current Deferred Revenue is $2.4 million, which was down 9048.85% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Current Deferred Revenue registered a high of $28.4 million during Q1 2024, and its lowest value of $1.9 million during Q4 2021.
  • Moreover, its 5-year median value for Current Deferred Revenue was $10.2 million (2021), whereas its average is $13.4 million.
  • Per our database at Business Quant, Spero Therapeutics' Current Deferred Revenue surged by 30162.38% in 2023 and then plummeted by 9048.85% in 2025.
  • Quarter analysis of 5 years shows Spero Therapeutics' Current Deferred Revenue stood at $1.9 million in 2021, then surged by 234.95% to $6.2 million in 2022, then skyrocketed by 301.62% to $25.0 million in 2023, then decreased by 12.91% to $21.8 million in 2024, then tumbled by 89.05% to $2.4 million in 2025.
  • Its Current Deferred Revenue was $2.4 million in Q3 2025, compared to $5.4 million in Q2 2025 and $17.2 million in Q1 2025.